Kinnate Biopharma Inc (KNTE) Stock: What Does the Chart Say Monday?

Monday, November 13, 2023 11:22 AM | InvestorsObserver Analysts

Mentioned in this article

Kinnate Biopharma Inc (KNTE) Stock: What Does the Chart Say Monday?

Overall market sentiment has been high on Kinnate Biopharma Inc (KNTE) stock lately. KNTE receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Kinnate Biopharma Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on KNTE!

See Full KNTE Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With KNTE Stock Today?

Kinnate Biopharma Inc (KNTE) stock is higher by 6.87% while the S&P 500 is down -0.13% as of 11:01 AM on Monday, Nov 13. KNTE is higher by $0.08 from the previous closing price of $1.23 on volume of 65,088 shares. Over the past year the S&P 500 has gained 11.43% while KNTE is down -86.85%. KNTE lost -$2.82 per share in the over the last 12 months. To screen for more stocks like Kinnate Biopharma Inc click here.

More About Kinnate Biopharma Inc

Kinnate Biopharma Inc a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The company's product candidate is KIN-2787, which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor it is developing for the treatment of patients with lung cancer, melanoma and other solid tumors. Its KIN003 program is evaluating Fibroblast Growth Factor Receptors (FGFR) inhibitor candidates for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining. Click Here to get the full Stock Report for Kinnate Biopharma Inc stock.